急性一氧化碳中毒后迟发性脑病的临床表现和影像学特点

目的探讨急性一氧化碳中毒后迟发性脑病的临床表现和影像学特点及其诊断价值。方法回顾性对23例急性一氧化碳中毒后迟发性脑病的临床表现和影像学特点进行归纳和分析。结果23例患者中智能障碍23例（100％），言语功能障碍17例（73.9％），另有共济失调精神障碍帕金森综合症及尿失禁等。头部CT和MRI主要表现为皮层下脑白质异常信号及基底节区或苍白球区异常信号，极少累及大脑皮质脑干和小脑。结论急性一氧化碳中毒后迟发性脑病的诊断主要依靠病史和临床症状，MRI比CT更有诊断价值。     

氧化砷对小鼠腹水型肝癌细胞的作用

目的 :研究氧化砷对移植性腹水型肝癌细胞的抗癌作用。方法 :肝癌细胞 (1 8× 10 7)接种入小鼠腹腔。对照组注射NS(0 8mL) ,余组用氧化砷 (1,2 ,3μmol/L)腹腔注射 ,每日 1次 ,共 10日。结果 :第 10天腹水细胞计数 ,1,2和 3μmol/L组瘤细胞锐减 (P <0 0 5 ) ,但第 16天腹水肿瘤细胞急骤增加。结论 :氧化砷对腹水肿瘤细胞有暂时抑制作用。     

顺铂聚乳酸微球的药物释放特性及肝动脉栓塞研究

对顺铂聚乳酸微球进行了体外药物释放和家犬肝动脉栓塞研究。该微球粒径范围为50～200μm,平均粒径为115.76±35.94μm,顺铂含量为37.16%(W/W);体外药物释放机制符合Higuchi方程;肝动脉栓塞后8h,肝组织顺铂浓度高达21.55±12.18μg/g,明显高于肝动脉灌注顺铂组:3.16±0.09μg/g(P<0.05);肝动脉栓塞组的顺铂血浓峰值、各取血点浓度及曲线下面积AUC皆低于肝动脉灌注顺铂组。可望达到提高栓塞部位的药物疗效,降低全身毒副反应的作用。     

激活素A对人肝星状细胞系LI 90细胞增殖的影响

目的：检测激活素（ACT）A对肝星状细胞（HSC）系LI90细胞增殖的影响。方法：采用基因重组人ACT A（0．025－250ng/ml）、转化生长因子－β1（TGF－β1）、镦泡抑素（FS）处理体外培养的人HSC系LI90，采用四唑盐比色法（MTT法）检测其对细胞增殖的影响。结果：ACT A浓度在0.025-250ng/ml范围内，均可刺激LI90细胞增殖，0.025-25ng/ml浓度范围内的ACT A作用轻微，而250ng/ml的ACT A作用明显增强（P＜0．01）；相反，TGF－β1（2．5ng/ml）对LI90细胞增殖无明显影响；0．315ng/ml FS与浓度为0.25ng/ml的ACT A共同孵育可阻断ACT A促进LI90增殖的活性（P＜0．05），而0．315ng/ml FS单独作用对LI 90细胞生长明显影响。结论：ACT可促进HSC增殖，在肝纤维化发病机制中发挥重要作用。     

继发性肝癌的外科治疗

目的探讨继发性肝癌的手术适应证和方法。方法对52例继发性肝癌的临床病例资料进行回顾性分析。结果分别采用了左半肝切除、右半肝切除、左外叶切除、右前叶切除、右后叶切除和肝楔形切除术。术后1、3、5年的生存率分别为28.3%、19.4%和11.9%。结论对适合手术的继发性肝癌,行肝切除术可以获得满意的效果。     

Preoperative Chemotherapy for Colorectal Liver Metastases: Impact on Hepatic Histology and Postoperative Outcome

Some investigators have suggested that preoperative chemotherapy for hepatic colorectal metastases may cause hepatic injury and increase perioperative morbidity and mortality. The objective of the current study was to examine whether treatment with preoperative chemotherapy was associated with hepatic injury of the nontumorous liver and whether such injury, if present, was associated with increased morbidity or mortality after hepatic resection. Two-hundred and twelve eligible patients who underwent hepatic resection for colorectal liver metastases between January 1999 and December 2005 were identified. Data on demographics, clinicopathologic characteristics, and preoperative chemotherapy details were collected and analyzed. The majority of patients received preoperative chemotherapy (n = 153; 72.2%). Chemotherapy consisted of fluoropyrimidine-based regimens: 5-FU monotherapy, 31.6%; irinotecan, 25.9%; and oxaliplatin, 14.6%. Among those patients who received chemotherapy, the type of chemotherapy regimen predicted distinct patterns of liver injury. Oxaliplatin was associated with increased likelihood of grade 3 sinusoidal dilatation (p = 0.017). Steatosis >30% was associated with irinotecan (27.3%) compared with no chemotherapy, 5-FU monotherapy, and oxaliplatin (all p < 0.05). Irinotecan also was associated with steatohepatitis, as two of the three patients with steatohepatitis had received irinotecan preoperatively. Overall, the perioperative complication rate was similar between the no-chemotherapy group (30.5%) and the chemotherapy group (35.3%) (p = 0.79). Preoperative chemotherapy was also not associated with 60-day mortality. In patients with hepatic colorectal metastases, preoperative chemotherapy is associated with hepatic injury in about 20 to 30% of patients. Furthermore, the type of hepatic injury after preoperative chemotherapy was regimen-specific. Presented at the American Hepato-Pancreato-Biliary Association 2006 Annual Meeting, March 11, Miami, Florida.     

新生儿缺氧缺血性脑病血浆内皮素-1水平测定及临床意义

[目的]研究新生儿缺氧缺血性脑病（hypoxic-ischemic encephlopathy,HIE）患儿血浆内皮素-1（E-1）的变化与病情严重程度之间的关系.[方法]采用放射免疫法测定36例HIE患儿及20例正常新生儿急性期和恢复期外周血ET-1的动态变化.[结果]HIE患儿急性期血浆ET-1与正常新生儿相比差异显著（P＜0.01）,且病情越严重者ET-1增高越明显.恢复期与正常组比较差异无显著性（P＞0.05）.[结论]新生儿HIE早期体内产生大量ET-1参与了HIE的病理生理过程.     

新生儿缺氧缺血性脑病神经元烯醇化酶变化的研究

目的　探讨新生儿缺氧缺血性脑病时神经元烯醇化酶的变化,为HIE的诊断和治疗提供依据。方法　采用病历对照研究,将实验组分为三组:轻、中、重度HIE分别为2 1、4 9、8例;正常对照组73例。测定其血中神经元烯醇化酶的浓度变化。比较各组间检测指标的差异。结果　实验组NSE水平明显高于对照组,组间有显著性差异,P <0 .0 1:且实验组轻、中、重度间有显著性差异,P均<0 .0 5。结论　NSE水平与HIE的病情严重程度相关,是反映HIE严重程度比较客观的指标。     

腹腔镜肝右后叶囊肿开窗引流术35例报告

目的：探讨肝右后叶肝囊肿的腹腔镜处理方法。方法：1998年1月～2005年12月对35例有症状的肝右后叶囊肿（21例主要位于Ⅵ段，14例主要位于第Ⅶ段）采用四孔法行囊肿开窗引流术。囊肿位于肝右后叶上段者采用肝上入路，胆囊牵引钳或三叶钳推压肝脏使其向前向下，暴露肝后囊肿，囊肿开窗，修剪带蒂大网膜放入囊肿。囊肿位于肝右后叶下段者采用肝下入路，超声刀切开肝结肠韧带，右三角韧带及肝肾间疏松组织，胆囊牵引钳抬起肝脏，囊肿开窗，大网膜放入囊腔引流。结果：35例肝右后叶肝囊肿均在腹腔镜下完成肝囊肿开窗引流术，无中转开腹手术。15例采用肝上入路，20例采用肝下入路。手术时间30～95min，平均46min。无手术并发症。35例病理检查结果均为先天性肝囊肿。术后症状均消失。术后住院2～5d，平均3．8d。35例随访6～36个月，平均34个月，33例无复发，2例（为肝上入路病例）囊肿未完全消失，但较术前明显缩小，无明显症状，观察半年未见增大。结论：肝下及肝上入路囊肿开窗引流是腹腔镜下处理肝右叶肝囊肿的有效方法。     

Repeat Transarterial Chemoembolization (TACE) for Progressive Hepatic Carcinoid Metastases Provides Results Similar to First TACE

Background Transarterial chemoemobolization (TACE) is commonly used to treat metastatic carcinoid tumors; however, the management of progressive disease is less clear. We sought to determine if patients with disease progression after TACE would benefit from repeat TACE. Methods The records of 27 patients undergoing repeat TACE for radiologic or symptomatic progression after TACE for metastatic carcinoid were reviewed and compared to 122 undergoing first TACE. Overall and progression-free survivals were estimated by the Kaplan–Meier method. Results Mean disease-free interval after first TACE was 11.8 months. Radiologic response was observed in 61% compared to 82% after first TACE (p = 0.058); hormone response in 64% compared to 80% (p = 0.159); and symptomatic response in 77% compared to 92% (p = 0.053). The complication rate after repeat TACE was lower than after first TACE (p = 0.03). Median overall survival was similar after repeat (28.1 months) and first TACE (33.3 months) (p = 0.53). Progression-free survival was shorter after repeat TACE but not significantly so. No factor examined could predict survival after repeat TACE. Conclusion Repeat TACE for patients with hepatic carcinoid metastases failing first TACE or having evidence of disease progression is safe and offers a viable treatment option. Presented at the 48th Annual Meeting of The Society for Surgery of the Alimentary Tract, Washington, DC, May, 2007.